Pharvaris Raises $132.3M in Upsized Share Offering
Event summary
- Pharvaris closed a $132.3M underwritten offering of 4.45M ordinary shares, including an additional 581,199 shares from underwriters' option.
- Proceeds will support development of deucrictibant for hereditary angioedema (HAE) and acquired angioedema (AAE-C1INH).
- Topline data from the CHAPTER-3 Phase 3 study for HAE prevention is expected in Q3 2026.
- CREAATE Phase 3 study for AAE-C1INH is ongoing.
The big picture
Pharvaris' $132.3M raise underscores investor confidence in oral bradykinin B2 receptor antagonists as a next-generation treatment for angioedema. The funding comes as the company races to deliver topline data from its pivotal CHAPTER-3 study, a critical inflection point for its lead asset, deucrictibant. Success here could position Pharvaris as a key player in a market increasingly shifting toward oral therapies.
What we're watching
- Clinical Milestones
- The pace at which deucrictibant's CHAPTER-3 and CREAATE studies progress will determine regulatory timelines and commercialization potential.
- Capital Deployment
- How Pharvaris allocates the $132.3M raise will signal priorities between HAE and AAE-C1INH indications.
- Market Positioning
- Whether Pharvaris can differentiate deucrictibant in a competitive HAE landscape dominated by established therapies.
Related topics